论文部分内容阅读
目的探讨应用血管紧张素转化酶抑制剂(ACEI)和(或)血管紧张素受体拮抗剂(ARB)降低尿蛋白未达标慢性肾炎患者加用安体舒通,观察降低尿蛋白及肾脏保护作用。方法将24例长期应用ACEI和ARB尿蛋白未达标患者联合安体舒通20 mg/d。检测0、2、4、8、16周后24 h尿蛋白、血肌酐、血钾、估算肾小球滤过率(eGFR)。结果治疗后第8、16周时尿蛋白较治疗前明显下降;且eGFR、血肌酐、血钾无显著变化。结论在应用ACEI和ARB基础上联合安体舒通对降低慢性肾炎患者尿蛋白有显著作用。
Objective To investigate whether angiotensin converting enzyme inhibitor (ACEI) and / or angiotensin receptor blocker (ARB) can reduce urinary protein and renal protection in patients with undetectable chronic nephritis . Methods 24 cases of long-term use of ACE inhibitors and ARB urine protein in patients with spironolactone 20 mg / d. 24 h urinary protein, serum creatinine and potassium levels were measured at 0, 2, 4, 8 and 16 weeks later to estimate glomerular filtration rate (eGFR). Results At the 8th and 16th week after treatment, urinary protein decreased significantly compared with that before treatment. There was no significant change in eGFR, serum creatinine and serum potassium. Conclusions The combination of ACEI and ARB on the basis of the combination of spironolactone in patients with chronic nephritis reduce proteinuria have a significant role.